Researchers overcome chemotherapy resistance in the lab

Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI).

Dr. Jerry Pelletier, PhD candidate Marie-Eve Bordeleau, and post-doctoral fellow Francis Robert, of the Department of Biochemistry and the McGill Cancer Centre – along with colleagues from Boston University, the Sloan-Kettering Cancer Center, the University of Vienna and the Howard Hughes Medical Institute – conducted an extensive study on a class of natural products known as cyclopenta benzofuran flavaglines (CBF).

Working with mice genetically modified to mimic human leukemias, they discovered that one particular CBF compound, silvestrol, can effectively re-sensitize tumors to chemotherapy, making them susceptible to the killing effects of anticancer drugs.

"One of the major problems with cancer therapy is that the tumours either fail to respond or stop responding over time to various chemotherapy drugs," Pelletier said. "One reasonable explanation for why this happens is the normal process of protein synthesis in the cell is usurped, principally because cancer cells grow faster and have higher metabolic needs. The normal checks and balances are no longer present."

Pelletier's lab at the Department of Biochemistry and McGill Cancer Centre focuses on high-throughput assays of various compounds to determine their anti-cancer effectiveness. One that showed promise was silvestrol, a natural compound derived from Aglaia silvestris, a large genus of trees and shrubs found in Malaysia, South China and some Pacific islands. It has been used in Malaysian folk medicine for generations, but never as a cancer therapy.

"We made a conscious decision early on in our research to also screen for natural products," Pelletier says. "Silvestrol is not a synthetic compound you can buy from commercial suppliers."

In the lab, Pelletier explained, silvestrol therapy re-sensitized leukemia cells which had already demonstrated resistance to the chemotherapy agent doxorubicin.

"Essentially, we have turned off the cancer cell's survival signals, which is associated with resistance," he said.

However, he cautioned, though synthetic silvestrol is now starting to become available, trials in humans and possible treatments are still many years away.

Source: McGill University

Related stories:

It's that time of year: Medicare shifts
This is the time of the year when we give thanks. And also talk about Medicare. The two topics are not necessarily related.
Iressa proves just as effective as chemotherapy for lung cancer
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.
Study identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
Survival of head and neck cancer patients is greatly affected by coexisting ailments
Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.
Scientists find cell pathway driving a deadly sub-type of breast cancer
An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women.
Proton therapy and concurrent chemotherapy may reduce bone marrow toxicity in advanced lung cancer
Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
Novel 4-drug combination proves safe for lung cancer treatment
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.

News discussion:

Medicine & Health news